Apnimed announces IPO plans while FDA reviews its sleep-apnea therapy
read at Endpoints ↗DealPositive
Apnimed, a Cambridge, Massachusetts biotech, disclosed that it will pursue an initial public offering on Nasdaq.
The move comes as the company’s lead sleep‑apnea candidate is under review by the U.S. Food and Drug Administration.
The filing marks the first formal IPO attempt after several years of exploring the option, and investors will watch the regulatory outcome closely.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Apnimed files for IPO as FDA reviews its sleep apnea drug”
read at Endpoints ↗82 words · retrieved Jul 10
comments(0)
5-min edit window · permanent after that